However, we should emphasize that although most BRAF and PI3K-mTOR inhibitors showed preferential sensitivity to cluster2 colon cancer cells, some other BRAF and PI3K-mTOR inhibitors showed not. This evidence concerns the gene MTOR and colonic neoplasm.